Beneficial Effects of Insulin Versus Sulphonylurea on Insulin Secretion and Metabolic Control in Recently Diagnosed Type 2 Diabetic Patients
- 1 August 2003
- journal article
- clinical trial
- Published by American Diabetes Association in Diabetes Care
- Vol. 26 (8), 2231-2237
- https://doi.org/10.2337/diacare.26.8.2231
Abstract
OBJECTIVE—To evaluate whether treatment with insulin in recently diagnosed type 2 diabetes is advantageous compared with glibenclamide treatment. RESEARCH DESIGN AND METHODS—β-Cell function, glycemic control, and quality of life were monitored over 2 years in 39 patients with islet cell antibody-negative type 2 diabetes diagnosed 0–2 years before inclusion in a Swedish multicenter randomized clinical trial. Patients were randomized to either two daily injections of premixed 30% soluble and 70% NPH insulin or glibenclamide (3.5–10.5 mg daily). C-peptide-glucagon tests were performed yearly in duplicate after 2–3 days of temporary withdrawal of treatment. RESULTS—After 1 year the glucagon-stimulated C-peptide response was increased in the insulin-treated group by 0.14 ± 0.08 nmol/l, whereas it was decreased by 0.12 ± 0.08 nmol/l in the glibenclamide group, P < 0.02 for difference between groups. After 2 years, fasting insulin levels were higher after treatment withdrawal in the insulin-treated versus the glibenclamide-treated group (P = 0.02). HbA1c levels decreased significantly during the first year in both groups; however, at the end of the second year, HbA1c had deteriorated in the glibenclamide group (P < 0.01), but not in the insulin-treated group. The difference in evolution of HbA1c during the second year was significant between groups, P < 0.02. A questionnaire indicated no difference in well-being related to treatment. CONCLUSIONS—Early insulin versus glibenclamide treatment in type 2 diabetes temporarily prolongs endogenous insulin secretion and promotes better metabolic control.Keywords
This publication has 18 references indexed in Scilit:
- Random C-peptide in the classification of diabetesScandinavian Journal of Clinical and Laboratory Investigation, 2000
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Increased Storage and Secretion of Islet Amyloid Polypeptide Relative to Insulin in the Spontaneously Diabetic GK RatPancreas, 1996
- Capillary Blood on Filter Paper for Determination of HbA1c by Ion Exchange ChromatographyDiabetes Care, 1996
- Relationships Between Diabetes Duration, Metabolic Control and β‐cell Function in a Representative Population of Type 2 Diabetic Patients in SwedenDiabetic Medicine, 1994
- The Effect of Chronic Hyperglycaemia on the Islet B-cell Responsiveness in Newly Diagnosed Type 2 DiabetesDiabetic Medicine, 1992
- Dose-Dependent Effects of Glyburide on Insulin Secretion and Glucose Uptake in HumansDiabetes Care, 1991
- Insulin and Atheroma: 20-Yr PerspectiveDiabetes Care, 1990
- Reproducibility of the Glucagon TestDiabetic Medicine, 1987
- C-peptide response to glucagon. A test for the residual beta-cell function in diabetes mellitusDiabetes, 1977